Compared to targets such as FAK and Src, which have been clinically tested in a wide range of tumours, ILK inhibitors are still in the laboratory or preclinical research stage, and there is a lack of data from large-scale clinical trials to fully assess their safety and efficacy. Here, PTK2 is linked to neoplasm.